<DOC>
	<DOCNO>NCT01212770</DOCNO>
	<brief_summary>The purpose study determine whether apremilast safe effective treatment patient psoriatic arthritis qualify psoriasis lesion . Apremilast propose improve sign symptom psoriatic arthritis ( tender swollen joint , pain , physical function ) treat patient .</brief_summary>
	<brief_title>PALACE 3 : Efficacy Safety Study Apremilast Treat Active Psoriatic Arthritis</brief_title>
	<detailed_description>Psoriatic arthritis ( PsA ) inflammatory arthritis occur 6-39 % psoriasis patient . The immunopathogenesis PsA , mirror identical see psoriatic plaque , reflect complex interaction among resident dendritic , fibroblastic endothelial cell , inflammatory cell attract synovium cytokine chemokines . Apremilast ( CC-10004 ) novel oral agent modulate multiple inflammatory pathway target phosphodiesterase type 4 ( PDE4 ) enzyme inhibition . Therefore , apremilast potential effective treatment PsA .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<criteria>Males female , age ≥ 18 year time consent . Have diagnosis Psoriatic Arthritis ( PsA , criterion ) ≥ 6 month duration . Meet Classification Criteria Psoriatic Arthritis ( CASPAR ) criterion PsA time screen . Must inadequately treat diseasemodifying antirheumatic drug ( DMARDs ) May axial involvement alone Concurrent Tx allow methotrexate , leflunomide , sulfasalazine Have ≥ 3 swollen AND ≥ 3 tender joint . Males &amp; Females must use contraception Stable dose NSAIDs , narcotic low dose oral corticosteroid allow . Have least one ≥2 cm psoriasis lesion Pregnant breast feeding . History allergy component investigational product Hepatitis B surface antigen and/or Hepatitis C antibody positive screening . Therapeutic failure &gt; 3 agent PsA &gt; 1 biologic tumor necrosis factor ( TNF ) blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Arthritis</keyword>
	<keyword>inflammation</keyword>
	<keyword>skin condition</keyword>
	<keyword>inflammatory cell</keyword>
	<keyword>apremilast</keyword>
	<keyword>CC-10004</keyword>
	<keyword>phosphodiesterase type 4</keyword>
</DOC>